This is the part two of a three-part series. Catch up on Part One here.
Preetham Srinivas, the head of the
chest radiograph project in Qure.ai, summoned Bhargava Reddy, Manoj Tadepalli, and
Tarun Raj to the meeting room.
“Get ready for an all-nighter, boys,”
Qure’s scientists began investigating
the algorithm’s mysteriously high performance on chest radiographs from a new
hospital. To recap, the algorithm had an area under the receiver operating
characteristic curve (AUC) of 1 – that’s 100 % on multiple-choice question
“Someone leaked the paper to AI,”
“It’s an engineering college joke,”
explained Bhargava. “It means that you saw the questions before the exam. It
happens sometimes in India when rich people buy the exam papers.”
Just because you know the questions
doesn’t mean you know the answers. And AI wasn’t rich enough to buy the AUC.
The four lads were school friends from
Andhra Pradesh. They had all studied computer science at the Indian Institute
of Technology (IIT), a freaky improbability given that only hundred out of a
million aspiring youths are selected to this most coveted discipline in India’s
most coveted institute. They had revised for exams together, pulling
all-nighters – in working together, they worked harder and made work more fun.
Can artificial intelligence help prevent cardiovascular diseases? Biotech startup, Prevencio, has developed a proprietary panel of biomarkers that uses blood proteins and sophisticated AI algorithms to detect cardiovascular conditions like coronary and peripheral artery disease, aerotic stenosis, risk for stroke and more. Dean Loizou, Prevencio’s VP of Business Development, breaks down the process step-by-step and explains exactly how Prevencio reports its clinically viable scores to doctors. How does the AI fit into all this? We get to that too, plus the details around this startup’s plans for raising a B-round on the heels of this work with Bayer.
Filmed at Bayer G4A Signing Day in Berlin, Germany, October 2019.
Being a patient or a carepartner can be a lonely, powerless
There’s no high powered legal or lobbying team to help support
you in your or your loved one’s health care journey. There’s no PR team at your
beck and call. There’s no advisory board, no executive committee, no
assistants, no chatbots or AI-powered technology coming to the rescue. There’s
no funding or a company sponsoring your efforts.
There’s no course in how to be a professional patient or
There’s no one there in the stillness and dark of the night, when
you are in the quiet of your thoughts, the privacy of your personal space,
where there are fleeting moments that you don’t have to be strong and
courageous. There is no one there to console you, support you as you lay there
willing to make a deal with the devil for the slightest glimmer of hope, the
slightest bit of clarity, or slightest bit of peace.
As a the carepartner to a loved one who is sick or disabled, many wouldn’t second guess charging head first through a thousand wielded swords if it meant a hope or a cure.
As an advocate, the majority of the work you do is self-created,
self-supported, and unpaid. A calling. An undeniable, magnetic force that pulls
you in because you cannot turn a blind eye no matter how hard you try. Because
you cannot bear witness to human suffering and not do anything. Because you’ve
been there and you can relate to another’s pain, grief, and sense of
hopelessness and it is unacceptable to not help ease the heaviness of another’s
Memorial Sloan Kettering Cancer Center is known worldwide for their leading-edge approach to cancer care…so, how can digital health help? MSK’s new Digital Ventures Lead, Janhvi Patel, talks about the types of tech companies she’s looking to partner with (or invest in) when it comes to advancing her organization’s oncology practice. Sure, precision medicine is an important area of innovation, but so are patient journey, provider workflow improvement, and data analysis. What else does one of the world’s leading cancer centers need to take their care to the next level? Tune in to meet Janhvi and find out.
Today on Health in 2 Point 00, everybody’s getting 20 million dollars! There are so many deals to cover. AI chatbot symptom checker Buoy gets $20 million, Clew gets $20 million, diabetes management company Oviva gets $21 million, Covera gets $23.5 million for diagnostic improvement in radiology, Zipari gets $22.5 million working on engagement in health plans. Another $20 million for Kaizen (yet another nonemergency medical transportation company), and Color raises $75 million for personal genetics testing. In other news, Google and Cerner—the catfight begins just in time so we don’t have to talk too much about interoperability at HIMSS. And if you were also waiting with bated breath for where Mona Siddiqui ended up, tune in for the gossip on this episode of Health in 2 Point 00. —Matthew Holt
Would it blow your mind if only five startup health plans interested in Medicare Advantage (MA) have collectively raised over $3.9 billion in private funding to-date? Well, readers, that is the reality. Now I know there are some skeptics out in the healthcare ecosystem, so I’m here to break down some of the investment thesis. Not going to necessarily defend, but explain some reasons why you should love and hate these investments. Let’s start with who raised these mind-boggling sums of money. The five startups are Oscar Health, Bright Health, Clover Health, Devoted Health, and Alignment Healthcare.
Oscar Health has raised $1.3 billion
Bright Health has raised $1.1 billion
Clover Health has raised $925 million
Devoted Health has raised $362 million
Alignment Healthcare has raised $240 million
I think it’s safe to say that the MA insurance market (also known as Medicare Part C) has captured the imagination of the venture capital and private equity community. The changing demographic trends of an aging baby boomer population, the increased selection of MA plans versus traditional Medicare fee-for-service (FFS), and the opportunity of technology-first MA startup plans to better reduce administrative fees (“Administrative Loss Ratio” or “ALR”) and control medical spend (“Medical Loss Ratio” or “MLR”) seems too good to pass up. If you were going to start a health plan, of all the lines of business you could be focused on, MA has highest profit margins, growing population, and better potential to impact patient spend and manage chronic diseases. It is certainly harder than writing the previous statement, but there are some real benefits versus the traditional commercial or Medicaid managed care.
Almirall is a dermatology-focused pharmaceutical company based in Spain, and its investment in R&D for developing new therapeutics leads the way as the largest within the country’s pharma industry. It’s no surprise, then, that Almirall has also adopted a digital therapeutics and digital health strategy to augment it’s molecular innovations with a ‘beyond the pill’ approach. We sat down with Almirall’s first-ever Chief Digital Officer, Francesca Wuttke, to hear about the pharma company’s digital strategy which is centered on laying the framework for advanced analytical platforms that gather more health data about patients and skin health. For help and fresh ideas, Francesca has opened Almirall’s doors to health tech startups, launching a brand-new accelerator program cutely called ‘Almirall’s Digital Garden,’ to ‘seed’ and ‘grow’ innovative solutions. Are there lots of health startups out there that focus on treating psoriasis, acne, and other dermatological conditions? Francesca tells us what she hopes ‘reap’ from the Digital Garden and how she hopes her broader digital strategy will flourish at the boutique pharma company.
Filmed at Barcelona Health Hub Summit in Barcelona, Spain, October 2019.
We’ve been spending a
lot of time these past few years debating healthcare reform. First the
Affordable Care Act was debated, passed, implemented, and almost continuously
litigated since. Lately the concept of Medicare For All, or variations on
it, has been the hot policy debate. Other smaller but still important
issues like high prescription drug prices or surprise billing have also
received significant attention.
As worthy as these all
are, a new study suggests that focusing on them may be missing the
point. If we’re not addressing wealth disparities, we’re unlikely to
address health disparities.
It has been well
documented that there are considerable health disparities in the U.S.,
attributable to socioeconomic status, race/ethnicity, gender, even geography, among other
factors. Few would deny that they exist. Many policy experts and
politicians seem to believe that if we could simply increase health insurance
coverage, we could go a long way to addressing these disparities, since coverage
should reduce financial burdens that may be serving as barriers to care that
may be contributing to them.
Universal coverage may
well be a good goal for many reasons, but we should temper our expectations
about what it might achieve in terms of leveling the health playing field.
As the adage goes, “health is wealth,” and Wellthy Therapeutics is a startup looking to improve the health of patients with chronic conditions in India by making treatment more accessible. Only 5% of Indians are insured and much of the population is not health literate, so CEO Abhishek Shah hopes the Wellthy app will fill a critical gap in care for those with type II diabetes, hypertension, cardiovascular conditions, and respiratory illnesses. With 15K users, the startup is focused on scaling up to truly capitalize on the potential of India’s enormous population. Learn more about their big plans, including those for a Series-A, to support that expansion.
Filmed at Bayer G4A Signing Day in Berlin, Germany, October 2019.